Showing 1-10 of about 129 articles.
Beyond Air™
GARDEN CITY, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air™
Award will help fund the development of high concentration nitric oxide (NO) for Nontuberculous Mycobacteria (NTM) pulmonary disease, which disproportionately affects cystic fibrosis (CF) patients ...
Beyond Air™
U.S. FDA reviewing premarket approval (PMA) submission for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), as Company prepares for commercialization Interim results...
Beyond Air™
GARDEN CITY, N.Y., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air™
Expect to dose first patient in January 2021 and report interim data mid-2021 Success in nontuberculous mycobacteria (NTM) at-home study paves the way to enter the much broader market treating severe...
Beyond Air™
GARDEN CITY, N.Y., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air™
Submitted a premarket approval (PMA) to the FDA for LungFit™ PH to treat persistent pulmonary hypertension of the newborn (PPHN) Expect patient enrollment to begin next week for the acute viral...
Beyond Air™
Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating improved economics and safety in hospital setting Will be subject to a 180-day review period by...
Beyond Air™
GARDEN CITY, N.Y., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air™
Patients with pneumonia caused by any virus, including SARS-CoV-2, will be considered for enrollment Study scheduled to start in November 2020 GARDEN CITY, N.Y., Oct. 21, 2020 (GLOBE NEWSWIRE) --...
Showing 1-10 of about 129 articles.
